Stonnington Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stonnington Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$364K	Hold	2,500	–	–	0.09%	175
2022 Q4	$382K	Hold	2,500	–	–	0.11%	152
2022 Q3	$331K	Sell	2,500 -1,800	-42%	-$274K	0.09%	157
2022 Q2	$681K	Sell	4,300 -2,300	-35%	-$354K	0.18%	118
2022 Q1	$1.06M	Buy	6,600 +4,100	+164%	+$595K	0.25%	89
2021 Q4	$374K	Hold	2,500	–	–	0.08%	190
2021 Q3	$340K	Hold	2,500	–	–	0.08%	197
2021 Q2	$458K	Hold	2,500	–	–	0.1%	183
2021 Q1	$440K	Buy	+2,500	New	+$411K	0.11%	176

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Stonnington Group's JAZZ Position: Q1 2023 in Review

Stonnington Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2023 at 2,500 shares worth $364K. The position accounts for 0.09% of the portfolio, ranked #175.

Stonnington Group first reported a position in JAZZ in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.06M in Q1 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Stonnington Group held 2,500 shares of Jazz Pharmaceuticals worth $364K as of Q1 2023.
Stonnington Group left its Jazz Pharmaceuticals share count unchanged in Q1 2023.
Jazz Pharmaceuticals made up 0.09% of Stonnington Group's portfolio in Q1 2023, its #175 holding.
Stonnington Group first reported a position in Jazz Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
Stonnington Group's Jazz Pharmaceuticals position peaked at $1.06M in Q1 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.